INTRODUCTION
The administration of exogenous surfactant has proven to be efficacious in the treatment and prevention of neonatal respiratory distress syndrome (RDS). However, premature infants may develop a secondary surfactant deficiency after treatment for their initial RDS if they suffer another acute lung injury, such as pulmonary hemorrhage, pneumonia/sepsis, or pulmonary edema. Inflammatory mediators and plasma proteins that pass into the alveolus may inactivate surfactant or damage type II pneumocytes, leading to secondary surfactant deficiency (SSD). 1, 2 In this retrospective, descriptive case series, we present data on three premature infants who had received 1 to 2 doses of Infasurf (Forest Laboratories, Inc.) between 13 and 18 days of life for an acute respiratory deterioration and after initial surfactant treatment for RDS. Blood gases and ventilatory settings were reviewed before and after the secondary surfactant administration. Chest radiographs were reviewed and interpreted by pediatric radiologists who were unaware of the secondary surfactant dosing.
CASE 1
Baby girl A was born at 26 weeks gestation to a 36-year-old primigravida mother with rupture of membranes (ROM) greater than 24 hours, by spontaneous vaginal delivery at a level III hospital. Birth weight was 835 g with Apgars of 2 1 and 7 5 . Her admitting diagnoses to the Neonatal Intensive Care Unit (NICU) were RDS, prematurity and rule out sepsis. She was placed on conventional ventilation and received one dose of surfactant. On day of life (DOL) 9, the infant was transported to the Medical University of South Carolina's NICU for increasing respiratory distress and patent ductus arteriosus (PDA) ligation.
On DOL 12, 2 days after PDA ligation, clinical deterioration (fever, lethargy, respiratory decompensation and hypotension) led to 7 days of antibiotics for presumed sepsis and pneumonia, in spite of negative blood cultures. Complete blood count's (CBC) remained normal. The infant required dopamine secondary to hypotension and subsequent renal failure.
On DOL 14, the infant required high-frequency oscillatory ventilation (HFOV) secondary to marked respiratory acidosis on conventional ventilation, using a moderate volume strategy (see Table 1 ). The chest X-ray (CXR) prior to dosing showed diffuse bilateral airspace disease consistent with pneumonia. One dose of surfactant was administered 2 hours after being placed on HFOV, with improvement in PCO 2 to the 40's. We were able to wean to conventional ventilation within 15 hours. The repeat CXR 24 hours later showed improved aeration. Graph 1 and Table 1 show the concomitant ventilator and blood gas parameters before and after dosing on DOL 14.
On DOL 16, the infant again decompensated, requiring the use of high-frequency jet ventilation (HFJV) with an end-expiratory pressure of 9. The infant continued to worsen despite HFJV, and on DOL 18 received a second dose of surfactant. The infant subsequently weaned on HFJV to conventional ventilation within 24 hours (Table 1) , at the same time that the CXR expansion improved, from low lung volumes with diffuse disease, to mild hyperinflation 24 hours later. She did not receive steroids or respiratory inhalants before or during secondary surfactant dosing, but had been on daily furosemide since DOL 9. The infant was transferred back to the referring level III facility at 23 days of age on conventional ventilation.
CASE 2
Baby boy B was born at 24 5 7 weeks gestation to a 31-year-old multiparous mother with twin gestation, gestational diabetes and a urinary tract infection. ROM occurred less than 18 hours prior to delivery. The mother received one dose of steroids shortly before delivery. The infant was born at an outlying facility and transported to our NICU. Birth weight was 695 g, with Apgars of 7 1 and 8 5 . Admitting diagnoses were RDS, infant of a diabetic mother, prematurity and rule out sepsis. On admission, he was placed on conventional ventilation and received three doses of surfactant.
On DOL 17, the infant was treated for presumed infection and pneumonia, but required increasing oxygen and ventilatory support on conventional ventilation. All cultures were negative and the CBC was normal. The CXR prior to dosing showed a marked worsening aeration with almost complete opacification on the right and diffuse lung disease on the left. The infant received two doses of surfactant 14 hours apart. Graph 2 and Table 2 illustrate the drop in PCO 2 with surfactant administration while the ventilator rate and FiO 2 were also decreasing. Within 48 hours of dosing, the infant was extubated to continuous positive airway pressure (CPAP). The follow-up CXR 24 hours after the first dose, showed improved aeration with minor atelectasis in the right lower lobe and bilateral diffuse lung disease. The infant did not receive steroids, diuretics or respiratory inhalants before or during secondary surfactant dosing. The infant was weaned to nasal cannula oxygen by DOL 20, and discharged on nasal cannula oxygen on DOL 72 at 34 3 7 weeks postconceptual age.
CASE 3
Baby girl C was born at 26 weeks gestation to a 26-year-old gravida 2, para 1, mother whose pregnancy was complicated by ROM more than 24 hours prior to emergency caesarean section for fetal distress. The mother received two doses of antenatal steroids. Birth weight was 720 g, and Apgars were 1 1 , 4 5 and 5
10
. Her admitting diagnoses were RDS, suspected sepsis and prematurity. On admission, she was placed on conventional ventilation, given four doses of surfactant, and 7 days of antibiotics for presumed sepsis.
On DOL 11, the infant was worked up for sepsis due to lethargy and hypotension and was started on antibiotics and physiologic dose hydrocortisone. She could not be oxygenated on conventional ventilation and required HFJV. The infant initially responded well to HFJV on an end-expiratory pressure of 6 with improvement in oxygenation but went on to develop significant carbon dioxide (CO 2 ) retention over the next 12 hours. All cultures were negative, white blood cell count, hematocrit and platelets remained normal, and the initial bandemia resolved within 24 hours. CXR prior to dosing showed increased opacification bilaterally. An echocardiogram completed at this time showed no PDA. On DOL 12, the infant received one dose of surfactant with a decrease in PCO 2 within 1 hour of dosing (Graph 3). HFJV was quickly weaned to conventional ventilation, with continued weaning of FiO 2 , peak inspiratory pressures and rate over the next 12 hours, while arterial blood gases (ABG) were improving (Table 3) . At 24 hours after surfactant, both oxygenation and ventilation began to worsen, but the infant did not receive additional doses. The CXR at 24 hours showed increasing opacification consistent with pneumonia. The infant did not receive diuretics, respiratory inhalants or additional steroids during the course of secondary surfactant treatment. The infant remained intubated until DOL 136, and was discharged home DOL 164 on nasal cannula oxygen, albuterol and fluticasone.
DISCUSSION
Classic, untreated neonatal RDS has a predictable time course of worsening pulmonary edema over 1 to 3 days, then recovery and diuresis over the next 2 to 3 days. Infants who experience respiratory decompensation on or after the first 7 days of life from pneumonia/sepsis, pulmonary hemorrhage or aspiration are at risk for surfactant dysfunction due to injury to the type II alveolar cells. [3] [4] [5] [6] [7] [8] [9] [10] Atelectasis, capillary leak of fluid and protein, alveolar inflammation, and the release of inflammatory mediators may cause surfactant inhibition and contribute to the development of chronic lung disease in premature infants. Mechanical ventilator pressures and the resulting volutrauma causes elastosis and fibrosis at the gas exchanging units and alveolar ducts.
11 Although secondary surfactant deficiency or inhibition may not be the sole determinant of the damage seen with chronic lung disease, surfactant administration during secondary insults may acutely improve pulmonary mechanics and help mitigate the inflammatory cascade, as seen in Nishina's animal study of acute lung injury due to aspiration. 12 It has also been demonstrated that decreased surface activity can be reversed by raising surfactant concentrations. 13 A few studies have demonstrated a positive response to secondary surfactant administration in infants and children who have had clinical evidence of respiratory failure. 3, 4 In one pilot study, 28 term and preterm infants with pneumonia, meconium aspiration or RDS were given 1 to 3 additional surfactant doses.
14 These infants were less than 4 days of age and were placed on HFJV for clinical deterioration after initial surfactant therapy. Only the 13 preterm infants in the study showed significant improvement in ventilatory and blood gas parameters with secondary surfactant administration while on HFJV. Another pilot study of 10 infants found surfactant to be effective in decreasing oxygen requirements in neonates between 9 and 30 days of age with early chronic lung disease. 15 Our case series also reports favorable short-term improvements in multiple ventilatory and blood gas parameters in neonates between 1 and 3 weeks of age with secondary surfactant administration. Deterioration 12 hours after dosing may indicate the need for additional doses. Pilot clinical trials using both shortand long-term clinical outcomes are needed to evaluate the efficacy of administering surfactant to neonates who experience secondary respiratory failure after recuperation from their initial respiratory distress.
